



Universiteit
Leiden
The Netherlands

Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia

Grimm, S.H.

Citation

Grimm, S. H. (2019, February 20). *Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia*. Retrieved from <https://hdl.handle.net/1887/68880>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/68880>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/68880> holds various files of this Leiden University dissertation.

Author: Grimm, S.H.

Title: Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia

Issue Date: 2019-02-20

Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia

1. The possibility to work together with good students greatly improves the scope and quality of a thesis. *This thesis*.
2. Considering the amount of resources necessary to produce a series of compounds, it is imperative to learn as much as possible from each synthesized molecule and not to be satisfied with one data point. *This thesis, chapter 3 and chapter 5*.
3. Especially if synthesis of new inhibitors is going well, it is important not to lose sight of the goal and produce compounds that actually answer questions when tested. *This thesis, chapter 5*.
4. The difficulty to treat a disease shows prominently if an improvement of 4-year overall survival from 44% to 51% has to be called a breakthrough therapy. *Blood* **2017**, 129, 3403–3406.
5. It is a pleasant surprise, if a chemical reaction has a broader scope than expected. *Org. Lett.* **2013**, 15, 6226–6229.
6. Only showing strong inhibitory effect of an inhibitor against several Kinases and promoting it “because of its potential selectivity” is worrying at best. *Blood* **2017**, 129, 257-260.
7. Pharmaceutical industry is hedging against inherent uncertainty in drug discovery with increased numbers. It remains to be seen how academia fits into this.
8. When working in science, one of the most difficult things is to get used to being one of the three blind men describing an elephant.
9. Opposition to publishing in open access journals is egoistic, short sighted and only helps to further divide the scientific community from the broader public.
10. Hear all, trust nothing. *Rules of Acquisition, Number 190*.